Your browser doesn't support javascript.
loading
Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.
Montgomery, A Bruce; Rhomberg, Paul R; Abuan, Tammy; Walters, Kathie-Anne; Flamm, Robert K.
Affiliation
  • Montgomery AB; Cardeas Pharma, Seattle, Washington, USA Bruce.Montgomery@CardeasPharma.com.
  • Rhomberg PR; JMI Laboratories, North Liberty, Iowa, USA.
  • Abuan T; Cardeas Pharma, Seattle, Washington, USA.
  • Walters KA; Cardeas Pharma, Seattle, Washington, USA.
  • Flamm RK; JMI Laboratories, North Liberty, Iowa, USA.
Antimicrob Agents Chemother ; 58(7): 3714-9, 2014 Jul.
Article in En | MEDLINE | ID: mdl-24752275
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Tract Infections / Amikacin / Gram-Negative Bacterial Infections / Fosfomycin / Gram-Negative Bacteria / Anti-Bacterial Agents Type of study: Guideline Language: En Journal: Antimicrob Agents Chemother Year: 2014 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Tract Infections / Amikacin / Gram-Negative Bacterial Infections / Fosfomycin / Gram-Negative Bacteria / Anti-Bacterial Agents Type of study: Guideline Language: En Journal: Antimicrob Agents Chemother Year: 2014 Document type: Article Affiliation country: United States Country of publication: United States